EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lutetium-177 Radiolabeled Gold Nanoparticles for Prostate Cancer Theranostics

Adamantia Apostolopoulou iD, Evangelia-Alexandra Salvanou iD, Christos Liolios, Stavros Xanthopoulos, Przemysław Koźmiński iD, Penelope Bouziotis iD

Nanomaterials · 04.04.2026 · 16 (7) · 441

DOI: 10.3390/nano16070441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nanomaterials, online erschienen am 04.04.2026. Verfasst von Adamantia Apostolopoulou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Radiochemical Studies Laboratory, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gold nanoparticles (AuNPs) have been extensively studied in cancer treatment research since they have special physicochemical characteristics such as facile surface functionalization with various chemical groups, low toxicity, favorable biocompatibility, and the ability to passively accumulate in tumors through the enhanced permeability and retention (EPR) effect. Prostate cancer cells exhibit an overexpression of the Prostate-Specific Membrane Antigen (PSMA), which therefore represents an ideal candidate for the development of nanoplatforms targeting PSMA overexpressed on these cells. Lutetium-177 (177Lu) is a β-particle emitter with a half-life of 6.7 days. This radionuclide is very promising for the development of theranostic platforms as it emits β− particles, which are suitable for therapy, and γ-photons, capable of SPECT imaging. The combination of 177Lu with AuNPs functionalized with PSMA for targeted delivery offers a promising tool for both diagnosis and therapy of prostate cancer. In this study, we focused on the synthesis and in vitro evaluation of PSMA-targeted AuNPs radiolabeled with 177Lu. The AuNPs were functionalized with the TADOTAGA chelator, which enables effective radiolabeling with the radiometal, as well as with a PSMA molecule, which comprises the PSMA targeting moiety (vehicle) of the nanoconstruct. Radiolabeling of the functionalized AuNPs with 177Lu was fast and robust. Subsequent studies focused on the in vitro stability and cellular interaction with two prostate cancer cell lines with different PSMA expression levels, in both 2D and 3D cell cultures, to assess effective targeting. Results indicate that radiolabeled AuNPs exhibit selective interaction with PSMA-expressing cells and present a stronger in vitro cytotoxic effect when functionalized with the PSMA molecule, confirming their potential as theranostic agents and warranting further investigation in LNCaP tumor-bearing mice.

Schlagwörter

Stichwörter der Autor:innen

MTT assayPSMAcell bindingcell internalizationgold nanoparticleslutetium-177prostate cancerradiolabelingspheroids

Autor:innen und Institutionen

  • Radiochemical Studies Laboratory, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Agia Paraskevi, 15341 Athens, Greece.
  • Department of Medicine, National and Kapodistrian University of Athens, Mikras Asias 75, 11527 Athens, Greece.
  • Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zographou, 15771 Athens, Greece.
  • Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.

ORCID-Profile: Adamantia Apostolopoulou, Evangelia-Alexandra Salvanou, Przemysław Koźmiński, Penelope Bouziotis

Zitieren

APA

Apostolopoulou, A., Salvanou, E. A., Liolios, C., Xanthopoulos, S., Koźmiński, P., & Bouziotis, P. (2026). Lutetium-177 Radiolabeled Gold Nanoparticles for Prostate Cancer Theranostics. Nanomaterials, 16(7), 441. https://doi.org/10.3390/nano16070441

Vancouver

Apostolopoulou A, Salvanou EA, Liolios C, Xanthopoulos S, Koźmiński P, Bouziotis P. Lutetium-177 Radiolabeled Gold Nanoparticles for Prostate Cancer Theranostics. Nanomaterials. 2026;16(7):441. doi:10.3390/nano16070441

BibTeX
@article{Apostolopoulou2026,
  author = {Apostolopoulou, Adamantia and Salvanou, Evangelia-Alexandra and Liolios, Christos and Xanthopoulos, Stavros and Koźmiński, Przemysław and Bouziotis, Penelope},
  title = {Lutetium-177 Radiolabeled Gold Nanoparticles for Prostate Cancer Theranostics},
  journal = {Nanomaterials},
  year = {2026},
  volume = {16},
  number = {7},
  pages = {441},
  doi = {10.3390/nano16070441}
}
Kostenlos starten →